I-Mab Biopharma expands collaboration with WuXi Biologics

China’s WuXi Biologics (HK: 2269) and biotech firm I-Mab Biopharma have expanded their strategic collaboration and licensed proprietary WuXiBody Platform to develop three bispecific antibodies (Bsab). WuXi Biologics will also be the exclusive partner to develop and manufacture these bispecifics.

Under the terms of the agreement, I-Mab has rights to use the proprietary WuXiBody platform to research, develop and commercialize three bispecific antibodies generated from I-MAB's proprietary pipeline. WuXi Biologics will receive an undisclosed upfront payment as well as development, regulatory and commercial milestone payments, and will be entitled to royalties based on global sales of these bispecific antibodies.

In July this year, I-Mab Biopharma also signed a deal with Korea's ABL Bio Corporation focusing on bispecific antibodies.